View Single Post
Old 11th December 2020, 05:30 PM   #8
Skeptic Ginger
Nasty Woman
 
Skeptic Ginger's Avatar
 
Join Date: Feb 2005
Posts: 87,756
According to the Regeneron webpage: Re 3rd phase clinical trials
Quote:
CASIRIVIMAB AND IMDEVIMAB
SARS-CoV-2 Virus Multi-Antibody Therapy Treatment for certain hospitalized and non-hospitalized patients with COVID-19; prevention of COVID-19 in household contacts of diagnosed patients
Company news releases REGENERON’S CASIRIVIMAB AND IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 IS FIRST COMBINATION THERAPY TO RECEIVE FDA EMERGENCY USE AUTHORIZATION
Quote:
Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients

Initial doses will be made available to approximately 300,000 patients, with no medication out-of-pocket costs, under U.S. government allocation program ...

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.
Skeptic Ginger is offline   Quote this post in a PM   Nominate this post for this month's language award Copy a direct link to this post Reply With Quote Back to Top